Central nervous system (CNS) disorders represent one of the leading causes of global
health burden. Nonetheless, new therapies approved against these disorders are among …

Antibodies are essential in modern life sciences biotechnology. Their architecture and
diversity allow for high specificity and affinity to a wide array of biochemicals. Combining …

Minimal therapeutic advances have been achieved over the past two decades for
glioblastoma (GBM), which remains an unmet clinical need. Here, hypothesis‐driven stimuli …

Glioblastoma (GBM) is the most common primary malignant brain cancer in adults with a
dismal prognosis. Temozolomide (TMZ) is the first‐in‐line chemotherapeutic; however …

Exosomes are nano-vesicles released by tumor cells to modulate extracellular environment.
Accumulating evidence revealed that glioblastoma derived exosomes contain multiple pro …

Delivery of most drugs into the central nervous system (CNS) is restricted by the blood–brain
barrier (BBB), which remains a significant bottleneck for development of novel CNS-targeted …

Endothelial cells play the most important role in construction of the blood–brain barrier.
Many studies have opted to use commercially available, easily transfected or immortalized …

Brain tumors are characterized by very high mortality and, despite the continuous research
on new pharmacological interventions, little therapeutic progress has been made. One of the …

The blood-brain barrier (BBB) is an essential structure of the central nervous system (CNS),
and its existence makes the local internal environment of the CNS a relatively independent …

The human immunodeficiency virus (HIV) uses the brain as reservoir, which turns it as a
promising target to fight this pathology. Nanoparticles (NPs) of poly (lactic-co-glycolic) acid …